Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other ...

MK-0616, an experimental oral medication aimed at reducing LDL cholesterol, is intended to be the first oral PCSK9 inhibitor.

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA ® at medical conferences and a planned KOL event MDNA11 ...

Merck’s stock just broke above its 50-day simple moving average, signaling a potential short-term bullish trend despite ...

It boasts more than 80 programs in phase 2 or phase 3 studies. Even with a 25% success rate for these, that should translate ...

Bristol Myers BMY depends on newer drugs like Opdualag, Reblozyl and Breyanzi to stabilize its revenue base as its legacy ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Jefferies analyst Akash Tewari remains bullish on Merck, maintaining a Buy rating and a $138 price target. The firm’s ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best and Cheap Stocks to Buy Now. On June 18, Akash Tewari, an analyst from ...

Keytruda (pembrolizumab) is approved for head and neck squamous cell carcinoma as a perioperative treatment regimen.

On 16 March 2024, New Delhi Police arrested Neeraj Chauhan and others for selling fake anti-cancer drugs to patients at a ...